MedTrace Logo

Apixaban in Patients With Left Ventricular Thrombus

NCT05208398 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-01-26

No results posted yet for this study

Summary

Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarction (MI).

Conditions

  • Left Ventricular Thrombus

Interventions

DRUG

Apixaban

5 mg twice daily, on top of standards of care.

DRUG

Warfarin

Warfarin, oral tablets, to achieve international normalized ratio (INR) of 2-3, on top of standards of care, as per updated guidelines of acue coronary syndrome management recommendations

Sponsors & Collaborators

  • Saud Al Babtain Cardiac Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-18
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05208398 on ClinicalTrials.gov